Small Cell Lung Cancer

▪        Address the leading cause of lung cancer, such as smoking.

▪        Systematically incorporate cost-benefit analyses into clinical trials, including health economic measures such as the incremental cost-effectiveness ratio, to support clinical decision-making (e.g., ultra-low-dose immunotherapy).

▪        Identify predictive biomarkers for response to specific targeted therapies and immunotherapy.

▪        Improve preclinical models for testing novel drugs.

▪        Identify tools for assessing quality of life in clinical trials.